Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01565148
Other study ID # 2010-007-03-DME
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received March 15, 2012
Last updated June 24, 2013
Start date February 2012
Est. completion date December 2013

Study information

Verified date June 2013
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

- To assess the safety of repeated iCo-007 intravitreal injections in treatment of subjects with diabetic macular edema as monotherapy and in combination with ranibizumab or laser photocoagulation

- To assess the change in visual acuity and retinal thickness on OCT from baseline to month 8 and month 12


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 208
Est. completion date December 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age =18 years

- Have diabetes mellitus type I or II (insulin or non-insulin dependent) with HbA1c =5.5% and HbA1c =13%; have non-proliferative diabetic retinopathy, or inactive proliferative diabetic retinopathy, or proliferative diabetic retinopathy with a reasonable expectation that panretinal photocoagulation will not be required during the study follow-up period

- Have diabetic macular edema with central subfield thickness of =250 microns (confirmed by Stratus TD OCT

- Have best corrected visual acuity (ETDRS) that is Snellen equivalent of

- 20/32 and =20/320, inclusive

- Be willing and able to sign an approved written informed consent. If a patient has a central nervous system disorder (i.e. dementia) that will not allow him/her to understand the consent independently, the patient will not be allowed to join the study

- Be able to attend all scheduled study visits

- Women who are not lactating or pregnant and are willing to use adequate contraception during the study period, if appropriate

Exclusion Criteria:

- Have macular or perimacular edema secondary to an etiology other than diabetes

- Have concurrent retinal diseases other than diabetic retinopathy

- Have additional ocular diseases compromising visual acuity and/or interfering with study assessments; patients who have glaucoma but deemed stable (intraocular pressure = 25 mmHg at screening) on medications or status post surgery, may participate in the study

- Participant has a history of prior pars plana vitrectomy

- Subjects with significant cataract or or posterior capsular opacification that may need intervention within one year or vitreous opacity that hinder study assessment (i.e.fundus examination) which requires intervention within a year

- Subjects who have DME with severe capillary non-perfusion (avascular zone diameter >1,000 microns)

- Have an allergy to fluorescein dye

- Have terminal renal disease (on active kidney dialysis), cerebral vascular accident(including TIA), myocardial infarction or congestive heart disease within 6 months of study enrollment, liver damage (2x upper limit of normal range for AST, ALT or total bilirubin). Patients who may have received renal transplant in the past and now have stable renal function, may participate in the study

- Subjects with systolic blood pressure higher than 180 mm Hg or diastolic above 100 mm Hg, with or without anti-hypertensive treatment

- Have a history of panretinal photocoagulation (PRP) in the study eye within 3 months of study entry or are likely to have PRP in the study eye during study participation

- Had macular photocoagulation or ocular surgery within 3 months of study entry in the study eye

- Received intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 3 months of study entry or anti-angiogenic drugs (pegaptanib sodium, ranibizumab, bevacizumab, VEGF-TRAP, protein kinase C inhibitor, etc.) within 2 months of study entry; history of usage of topical or systemic steroids within 3 months of study entry is not an exclusion

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
iCo-007 350 mcg
iCo-007 (350 µg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 µg) at month 4
iCo-007 700 mcg
iCo-007 (700 µg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 µg) at month 4
iCo-007 350 mcg Plus Laser
iCo-007 (350 µg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 µg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Ranibizumab Plus iCo-007 350 mcg
Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 µg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 µg) 2 weeks later

Locations

Country Name City State
United States Stanley M Truhlsen Eye Institute Omaha Nebraska

Sponsors (3)

Lead Sponsor Collaborator
Quan Dong Nguyen iCo Therapeutics Inc., Juvenile Diabetes Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in VA from baseline to month 8 The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 8 Baseline to month 8 No
Secondary Number of participants in a given study arm experiencing the same drug-related serious adverse event as a measure of safety and tolerability Safety of repeated iCo-007 intravitreal injections in treatment of subjects with DME as monotherapy and in combination with ranibizumab or laser photocoagulation. Serious consideration will be given if 2 or more patients in a particular treatment arm experience the same drug-related serious adverse event; Baseline to month 12 Yes
Secondary Change in VA from baseline to month 12 Baseline to month 12 No
Secondary Change in retinal thickness measured by OCT from baseline to month 8 Baseline to month 8 No
Secondary Change in retinal thickness measured by OCT from baseline to month 12 Baseline to month 12 No
Secondary Duration of iCo-007 treatment effect during the 12 month follow-up period as measured by VA and OCt thickness Baseline to month 12 No
Secondary Peak plasma concentration (Cmax)of iCo-007 after multiple injections Baseline to month 12 No
See also
  Status Clinical Trial Phase
Completed NCT03953807 - A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated Phase 4
Completed NCT03622580 - A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Phase 3
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Terminated NCT04611152 - A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Terminated NCT04603937 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Phase 3
Active, not recruiting NCT04108156 - This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Withdrawn NCT03629210 - Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema Phase 2
Withdrawn NCT02842541 - Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema Phase 1
Completed NCT02221453 - Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide Phase 2
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Completed NCT02979665 - Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema
Completed NCT02000102 - Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab N/A
Completed NCT02088229 - Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema N/A
Terminated NCT00779142 - Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies N/A
Completed NCT01171976 - Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus Phase 3
Completed NCT00989989 - Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema Phase 3
Terminated NCT00768040 - Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Phase 2
Completed NCT00683176 - Effect of Choline Fenofibrate (SLV348) on Macular Edema Phase 2
Completed NCT01259609 - Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy N/A